Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
WEB1 day ago · In March, Novo Nordisk shared monlunabant update during its Capital Markets Day 2024. In Phase 1, monlunabant produced a statistically significant mean weight loss of 3.5 kg (3.3%) compared to 0.6 ...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB1 day ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
News Details - novonordisk.com
WEB2 days ago · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in ...
Novo Nordisk Stock Declines After Headline Results From Mid …
WEB1 day ago · Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant ...
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
WEB1 day ago · Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk’s obesity newcomer monlunabant heads into …
WEB1 day ago · Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity. The trial showed significant weight loss with a 10 mg dose, achieving a 7.1 kg reduction versus 0.7 kg for placebo. Mild to moderate side effects were reported. A Phase IIb trial is planned for 2025
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
WEB1 day ago · Friday, shares of Novo Nordisk A/S are sliding following the announcement of safety results of phase 2a clinical trial of Monlunabant compared to placebo in patients with obesity and metabolic syndrome.Monlunabant, formerly INV-202, is a small molecule oral cannabinoid receptor 1 or CB1 inverse agonist. The trial investigated efficacy and safety, and post 16 weeks, people treated with a once ...
Novo’s obesity drug linked to ‘neuropsychiatric side effects’
WEB1 day ago · In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it seems the CB1 receptor blocker may face some familiar problems ...
Novo Nordisk's experimental weight loss pill has some ... - Yahoo
WEB1 day ago · Novo Nordisk stock fell nearly 6% during Friday morning trading after it posted the results. The Danish pharma giant tested monlunabant, a drug it acquired in 2023 with its $1 billion purchase of ...
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
WEB1 day ago · Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses. The company said a Phase ...
- Some results have been removed